Displaying drugs 1276 - 1300 of 1988 in total
HCV-086
HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus.
Investigational
AKI-001
AKI-001 is an aurora kinase inhibitor.
Experimental
Matched Iupac: … 5-ethyl-7,7,16-trimethyl-5,11,14,15-tetraazapentacyclo[10.8.0.0^{2,10}.0^{4,8}.0^{13,17}]icosa-1(12), …
SD-0006
Investigational
MK-0557
MK0557 has been investigated for the treatment of Schizophrenia and Paranoid Schizophrenia.
Investigational
HSD-016
Hsd 016 is under investigation in clinical trial NCT00838461 (Study Evaluating the Safety, Pharmacokinetics (PK), and Pharmacodynamices (PD) of HSD-016).
Investigational
MK-0686
MK0686 has been used in trials studying the treatment of Osteoarthritis, Pain, Postoperative, and Neuralgia, Postherpetic.
Investigational
QGC-001
QGC001 has been used in trials studying the treatment of Essential Hypertension.
Investigational
ABT-072
ABT-072 is under investigation in clinical trial NCT00890318 (A Study in Healthy Adult Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetic Profiles of Multiple Doses of ABT-072 Used to Treat Hepatitis C).
Investigational
MK-0736
MK-0736 is under investigation in clinical trial NCT00679055 (A Study of How MK-0736 Affects Arterial Plaque (0736-006)(TERMINATED)).
Investigational
EC-0652
EC-0652 is under investigation in clinical trial NCT02202447 (Phase 1 of EC1169 In Patients With Recurrent MCRPC).
Investigational
CYC-065
CYC-065 is under investigation in clinical trial NCT03739554 (CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL).
Investigational
AVI-014
AVI-014 is a glycosylated, recombinant human granulocyte colony-stimulating factor (G-CSF).
Investigational
DCP-001
Investigational
MT-0169
MT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.
Investigational
SIG-007
SIG-007 is a gene therapy that consists of cells that are genetically modified with a non-viral vector to express human alpha-galactosidase A. Developed by Sigilon Therapeutics, t is being investigated for the treatment of Fabry Disease.
Investigational
BTZ-043
Investigational
ICG-001
Investigational
TSN-084
Investigational
TCB-008
TCB-008 is an Allogeneic CD3+ T lymphocyte ex vivo expanded expressing the gamma delta T-cell receptor.
Investigational
GL-0719
Investigational
NVD-001
Investigational
CER-001
CER-001 is a negatively charged lipoprotein particle comprising human recombinant apolipoprotein A-I and two phospholipids: sphingomyelin and dipalmitoylphosphatidylglycerol. It is under investigation for the treatment of lecithin-cholesterol acyltransferase (LCAT) deficiencies.
Investigational
LL-37
LL-37 is a human cathelicidin that inhibits viral replication and while also playing a role in host defense against infection.
Investigational
Displaying drugs 1276 - 1300 of 1988 in total